<DOC>
	<DOCNO>NCT01186471</DOCNO>
	<brief_summary>This study patient stable schizophrenia investigate effect nicotine arousal , cognitive task social cognition acute dose administration .</brief_summary>
	<brief_title>The Effect Nicotine Arousal , Cognition Social Cognition Schizophrenic Patients</brief_title>
	<detailed_description>This double-blind ( neither physician patient know name assign drug ) , placebo-controlled , randomize ( study drug assign chance ) , three-way-crossover trial ( patient may receive different intervention sequentially trial ) patient stable schizophrenia . The three-way-crossover treatment phase consist three blind treatment period separate wash period ( period allow entire administer drug eliminate body ) 2 7 day . The study duration patient approximately 8 week . Each patient enrol randomized receive Treatment A ( 1mg nicotine per dose ) , Treatment B ( 2mg nicotine per dose ) Treatment C ( placebo ) one treatment period . The study drug ( nicotine placebo ) administer three time daily Day 1 treatment phase mouth spray , separate 2 3 hour ( i.e . 0h ; 2 3h ; 4 6h post first dose ) . Three different block cognitive assessment follow , one drug administration . Safety evaluation include adverse event monitoring , vital sign clinical laboratory test . Each patient participate receive 3 identical study drug administration per dose day ( 2 3 hour ) , result overall dose 3 mg nicotine ( Treatment A ) , 6 mg nicotine ( Treatment B ) 0 mg nicotine ( Treatment C ) per dose day . By end study , 3-way crossover , patient receive 9 mg nicotine via mouth spray .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>In outpatient schizophrenia stably treat ( primary medication ) least 2 month antipsychotic therapy ( treatment 1 antipsychotic drug acceptable provide dose level stable &gt; 2 month ) . Fluctuations dose level primary antipsychotic treatment acceptable provide dose level remain constant 2 week prior dose A know ( site ) disease history least 12 month DSMIV criterion Schizophrenia Willing hospitalize treatment period study Body mass index ( BMI ) 18 35 kg/m2 , inclusive ( BMI = weight/height2 ) Women must : postmenopausal ( least 12 month ) , surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , abstinent ( discretion investigator/per local regulation ) , sexually active , practice highly effective method birth control must agree continue use method contraception throughout study Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test admission ( study period ) Smoking average minimum 15 cigarette ( equivalent ) per day within 6 month prior study drug administration ( Cohort 1 ) Female patient pregnant breastfeed Clinically significant abnormal value clinical chemistry , hematology urinalysis screening . It expect laboratory value generally within normal range laboratory , though minor deviation , consider clinical significance investigator , acceptable . Values alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2 fold ULN allow Clinically significant abnormal physical examination , vital sign 12lead ECG screen A DSMIV axis I diagnosis schizophrenia focus treatment cause disability last 6 month ( Major Depressive Episode ) Evidence substance dependence nicotine ( DSMIV ) last 6 month History current significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , unmanaged high BP , hematological disease , bronchospastic respiratory disease , renal hepatic insufficiency , Parkinson 's disease , infection ( HIV , Hepatitis C ) , illness Investigator considers exclude subject ( Subjects mild hypertension , lipid abnormality , diabetes mellitus thyroid disease allow significant treatment change require past 6 month ) Use antiparkinsonian agent past 2 month Suicidal risk ( assessed investigator ) , prior attempt suicide , command hallucination / hopelessness Smoking cigarette ( equivalent ) use nicotine base product within 3 month prior study drug administration ( Cohort 2 ) Current use medication smoke cessation nicotine replacement therapy , bupropion varenicline History epilepsy fit unexplained blackout</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Symptomatic treatment</keyword>
	<keyword>Cognition</keyword>
	<keyword>Cognitive deficit</keyword>
	<keyword>Schizophrenia</keyword>
</DOC>